← Leaderboards
Deborah J Anderson
Johns Hopkins University
$20,708,269
Attributed
$22,371,528
Total exposure
25
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,317,339 · 29
By mechanism
U19$18,851,953 · 3
P50$18,417,023 · 6
P01$5,086,175 · 3
R01$3,953,018 · 3
R33$3,591,477 · 2
U54$2,661,530 · 3
Top collaborators
- Thomas Ray Moench12 shared
- Kevin John Whaley12 shared
- Philip J Santangelo4 shared
- Kevin Whaley4 shared
- Lisa C Rohan1 shared
- Johnna S Temenoff1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Elizabeth Marion Jaffee$29,780,612
- William George Nelson$34,555,726
- Charles W. Flexner$41,000,447
- Peter A Merkel$19,482,229
- Michael A. Carducci$23,642,506
Others in their field
Top investigators on “Vagina”
- Tracey Devoir · Booz Allen Hamilton, Inc.$49,200,509
- James Ter Maat · Social And Scientific Systems, Inc.$49,025,547
- Thomas Hope · Northwestern University$29,067,774
- Alexa Fraser · National Opinion Research Center$26,867,847
- Francois J Villinger · Emory University$25,554,864
- Maria Mori Brooks · University Of Pittsburgh At Pittsburgh$23,967,448
Research focus
VaginaAntibodiesSexually Transmitted DiseasesMonoclonal AntibodiesWomanClinical ResearchFilmBaseCytokineSperm CellContraceptive MethodsSafetyProgramsPathogenCellsContraceptive AgentsNicotianaHiv-1PreventInnovationDesignClinical TrialsMicrobicideSeminal Fluid
Grant awards (86)
Antibody-based Contraceptive MPTs: Advancing the Human Contraceptive Antibody (HCA) through Clinical Trials$1,839,626
P50 · FY2025 · HD · contact PI
Project 3: Film Formulation, PK/PD and Safety Studies of ZB-06$605,199
P50 · FY2025 · HD · contact PI
Development of a bioadhesive vaginal film for extended release of MPT antibodies$518,754
R61 · FY2025 · HD
Core A: Administration$319,576
P50 · FY2025 · HD · contact PI
Antibody-based Contraceptive MPTs: Advancing the Human Contraceptive Antibody (HCA) through Clinical Trials$1,865,710
P50 · FY2024 · HD · contact PI
Project 3: Film Formulation, PK/PD and Safety Studies of ZB-06$533,568
P50 · FY2024 · HD · contact PI
Core A: Administration$286,420
P50 · FY2024 · HD · contact PI
Antibody-based Contraceptive MPTs: Advancing the Human Contraceptive Antibody (HCA) through Clinical Trials$1,804,492
P50 · FY2023 · HD · contact PI
Synthetic mRNA-mediated reversible immunocontraception$663,083
R33 · FY2023 · HD
Project 3: Film Formulation, PK/PD and Safety Studies of ZB-06$428,926
P50 · FY2023 · HD · contact PI
Core A: Administration$264,885
P50 · FY2023 · HD · contact PI
Antibody-based Contraceptive MPTs: Advancing the Human Contraceptive Antibody (HCA) through Clinical Trials$1,715,448
P50 · FY2022 · HD · contact PI
Synthetic mRNA-mediated reversible immunocontraception$647,780
R33 · FY2022 · HD
Project 3: Film Formulation, PK/PD and Safety Studies of ZB-06$451,104
P50 · FY2022 · HD · contact PI
Core A: Administration$212,581
P50 · FY2022 · HD · contact PI
Antibody-based Contraceptive MPTs: Preclinical and Clinical Research$1,813,579
P50 · FY2021 · HD · contact PI
Synthetic mRNA-mediated reversible immunocontraception$687,538
R33 · FY2021 · HD
Administrative Core$515,224
P50 · FY2021 · HD · contact PI
Preclinical Testing of Human Contraceptive Antibody (HCA) and HCA products$399,742
P50 · FY2021 · HD · contact PI
Antibody-based Contraceptive MPTs: Preclinical and Clinical Research$1,867,062
P50 · FY2020 · HD · contact PI
Preclinical Testing of Human Contraceptive Antibody (HCA) and HCA products$416,444
P50 · FY2020 · HD · contact PI
Project Three: Assessing effects of anti-CD52g Mabs on STD pathogens in semen$412,502
R01 · FY2020 · HD · contact PI
Synthetic mRNA-mediated reversible immunocontraception$380,465
R61 · FY2020 · HD
Administrative Core$349,439
P50 · FY2020 · HD · contact PI
Antibody-based Contraceptive MPTs: Preclinical and Clinical Research$2,042,218
P50 · FY2019 · HD · contact PI
Project Three: Assessing effects of anti-CD52g Mabs on STD pathogens in semen$626,613
R01 · FY2019 · HD · contact PI
Preclinical Testing of Human Contraceptive Antibody (HCA) and HCA products$436,853
P50 · FY2019 · HD · contact PI
Synthetic mRNA-mediated reversible immunocontraception$428,898
R61 · FY2019 · HD
Administrative Core$248,927
P50 · FY2019 · HD · contact PI
Antibody-based Contraceptive MPTs: Preclinical and Clinical Research$2,000,000
U54 · FY2018 · HD · contact PI
Project Three: Assessing effects of anti-CD52g Mabs on STD pathogens in semen$626,301
R01 · FY2018 · HD · contact PI
Preclinical Testing of Human Contraceptive Antibody (HCA) and HCA products$443,804
U54 · FY2018 · HD · contact PI
Administrative Core$217,726
U54 · FY2018 · HD · contact PI
Project One: Development and Testing of the HCA IVR$790,152
R01 · FY2017 · HD · contact PI
Project Three: Assessing effects of anti-CD52g Mabs on STD pathogens in semen$641,488
R01 · FY2017 · HD · contact PI
Seminal Microbiota Associated with Inflammation and HIV Transmission$205,677
R21 · FY2017 · AI · contact PI
Administrative Core$288,303
U19 · FY2016 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$288,303
U19 · FY2016 · AI · contact PI
Seminal Microbiota Associated with Inflammation and HIV Transmission$246,750
R21 · FY2016 · AI · contact PI
Use of Anti-CD52g Antibodies to Prevent HIV Transmission$204,625
R21 · FY2016 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$2,408,349
U19 · FY2015 · AI · contact PI
Administrative Core$677,349
U19 · FY2015 · AI · contact PI
MAbs in the Cervicovaginal Environment: Cellular Interactions and Host Defense$488,230
U19 · FY2015 · AI · contact PI
Use of Anti-CD52g Antibodies to Prevent HIV Transmission$245,550
R21 · FY2015 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$2,530,562
U19 · FY2014 · AI · contact PI
MAbs in the Cervicovaginal Environment: Cellular Interactions and Host Defense$326,580
U19 · FY2014 · AI · contact PI
Administrative Core$247,008
U19 · FY2014 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$27,182
U19 · FY2014 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$3,098,297
U19 · FY2013 · AI · contact PI
MAbs in the Cervicovaginal Environment: Cellular Interactions and Host Defense$368,060
U19 · FY2013 · AI · contact PI
Administrative Core$306,138
U19 · FY2013 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$3,573,839
U19 · FY2012 · AI · contact PI
MAbs in the Cervicovaginal Environment: Cellular Interactions and Host Defense$467,613
U19 · FY2012 · AI · contact PI
Administrative Core$325,542
U19 · FY2012 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$26,134
U19 · FY2012 · AI · contact PI
Monoclonal Antibody-based Multipurpose Microbicides$3,033,249
U19 · FY2011 · AI · contact PI
MAbs in the Cervicovaginal Environment: Cellular Interactions and Host Defense$228,701
U19 · FY2011 · AI · contact PI
Administrative Core$142,514
U19 · FY2011 · AI · contact PI
An In Vitro Model of Cell-Associated HIV-1 Transmission$440,766
R33 · FY2010 · AI · contact PI
An In Vitro Model of Cell-Associated HIV-1 Transmission$101,467
R33 · FY2010 · AI · contact PI
An In Vitro Model of Cell-Associated HIV-1 Transmission$438,287
R33 · FY2009 · AI · contact PI
Seminal HIV-1 Shedding and Drug Resistance in HIV-1/HSV-2 Coinfected Men on HAART$298,784
R56 · FY2009 · AI · contact PI
An In Vitro Model of Cell-Associated HIV-1 Transmission$159,296
R33 · FY2009 · AI · contact PI
An In Vitro Model of Cell-Associated HIV-1 Transmission$453,260
R33 · FY2008 · AI · contact PI
Seminal HIV-1 Shedding and Drug Resistance in HIV-1/HSV-2 Coinfected Men on HAART$647,202
R56 · FY2007 · AI · contact PI
An In Vitro Model of Cell-Associated HIV-1 Transmission$224,638
R21 · FY2007 · AI · contact PI
An In Vitro Model of Cell-Associated HIV-1 Transmission$192,790
R21 · FY2006 · HD · contact PI
Effects of STDs on HIV Immunity and Infectivity in Semen$80,750
R56 · FY2005 · DK
IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT$1,110,840
P01 · FY2004 · AI
IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT$61,947
P01 · FY2004 · AI
IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT$1,044,965
P01 · FY2003 · AI
HIV 1 IMMUNITY IN THE HUMAN MALE UROGENITAL TRACT$223,425
R01 · FY2003 · AI
HIV 1 IMMUNITY IN THE HUMAN MALE UROGENITAL TRACT$89,997
R01 · FY2003 · AI
IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT$814,531
P01 · FY2002 · AI
HIV 1 IMMUNITY IN THE HUMAN MALE UROGENITAL TRACT$244,412
R01 · FY2002 · AI
UPTAKE OF IG BY VAGINAL EPITHELIAL CELLS$180,480
P01 · FY2002 · AI
UPTAKE OF IG BY VAGINAL EPITHELIAL CELLS$180,480
P01 · FY2002 · AI
ACQUIRED IMMUNITY TO STD'S IN MALE GENITAL TRACT$0
P01 · FY2002 · AI
UPTAKE OF IG BY VAGINAL EPITHELIAL CELLS$180,480
P01 · FY2001 · AI
FACTORS AFFECTING VAGINAL IMMUNITY AND HIV INFECTION$40,640
R03 · FY2001 · TW
IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT$979,478
P01 · FY2000 · AI
HIV 1 IMMUNITY IN THE HUMAN MALE UROGENITAL TRACT$298,128
R01 · FY2000 · AI
UPTAKE OF IG BY VAGINAL EPITHELIAL CELLS$266,487
P01 · FY2000 · AI
UPTAKE OF IG BY VAGINAL EPITHELIAL CELLS$266,487
P01 · FY2000 · AI
FACTORS AFFECTING VAGINAL IMMUNITY AND HIV INFECTION$40,640
R03 · FY2000 · TW
ACQUIRED IMMUNITY TO STD'S IN MALE GENITAL TRACT$0
P01 · FY2000 · AI